| Date of Biosimilar FDA Approval |
Biosimilar Product |
Original Product
|
| March 2015 |
filgrastim-sndz/Zarxio |
filgrastim/Neupogen
|
| April 2016 |
infliximab-dyyb/Inflectra |
infliximab/Remicade
|
| August 2016 |
etanercept-szzs/Erelzi |
etanercept/Enbrel
|
| September 2016 |
adalimumab-atto/Amjevita |
adalimumab/Humira
|
| April 2017 |
infliximab-abda/Renflexis |
infliximab/Remicade
|
| August 2017 |
adalimumab-adbm/Cyltezo |
adalimumab/Humira
|
| September 2017 |
bevacizumab-awwb/Mvasi |
bevacizumab/Avastin
|
| December 2017 |
trastuzumab-dkst/Ogivri |
trastuzumab/Herceptin
|
| December 2017 |
infliximab-qbtx/Ixifi |
infliximab/Remicade
|
| May 2018 |
epoetin alfa-epbx/Retacrit |
epoetin alfa/Procrit
|
| June 2018 |
pegfilgrastim-jmdb/Fulphila |
pegfilgrastim/Neulasta
|
| July 2018 |
filgrastim-aafi/Nivestym |
filgrastim/Neupogen
|
| October 2018 |
adalimumab-adaz/Hyrimoz |
adalimumab/Humira
|
| November 2018 |
pegfilgrastim-cbqv/Udenyca |
pegfilgrastim/Neulasta
|
| November 2018 |
rituximab-abbs/Truxima |
rituximab/Rituxan
|
| December 2018 |
trastuzumab-pkrb/Herzuma |
trastuzumab/Herceptin
|
| January 2019 |
trastuzumab-dttb/Ontruzant |
trastuzumab/Herceptin
|
| March 2019 |
trastuzumab-qyyp/Trazimera |
trastuzumab/Herceptin
|
| April 2019 |
etanercept-ykro/Eticovo |
etanercept/Enbrel
|
| June 2019 |
trastuzumab-anns/Kanjinti |
trastuzumab/Herceptin
|
| June 2019 |
bevacizumab-bvzr/Zirabev |
bevacizumab/Avastin
|
| July 2019 |
rituximab-pvvr/Ruxience |
rituximab/Rituxan
|
| July 2019 |
adalimumab-bwwd/Hadlima |
adalimumab/Humira
|
| November 2019 |
pegfilgrastim-bmez/Ziextenzo |
pegfilgrastim/Neulasta
|
| November 2019 |
adalimumab-afzb/Abrilada |
adalimumab/Humira
|
| December 2019 |
infliximab-axxq/Avsola |
infliximab/Remicade
|
| June 2020 |
pegfilgrastim-apgf/Nyvepria |
pegfilgrastim/Neulasta
|
| July 2020 |
adalimumab-fkjp/Hulio |
adalimumab/Humira
|
| December 2020 |
rituximab-arrx/Riabni |
rituximab/Rituxan
|
| July 2021 |
insulin glargine-yfgn/Semglee |
insulin glargine/Lantus
|
| September 2021 |
ranibizumab-nuna/Byooviz |
ranibizumab/Lucentis
|
| December 2021 |
insulin glargine-aglr/Rezvoglar |
insulin glargine/Lantus
|
| December 2021 |
adalimumab-aqvh/Yusimry |
adalimumab/Humira
|
| February 2022 |
filgrastim-ayow/Releuko |
filgrastim/Neupogen
|
| April 2022 |
bevacizumab-maly/Alymsys |
bevacizumab/Avastin
|
| May 2022 |
pegfilgrastim-pbbk/Fylnetra |
pegfilgrastim/Neulasta
|
| August 2022 |
ranibizumab-eqrn/Cimerli |
ranibizumab/Lucentis
|
| September 2022 |
pegfilgrastim-fpgk/Stimufend |
pegfilgrastim/Neulasta
|
| September 2022 |
bevacizumab-adcd/Vegzelma |
bevacizumab/Avastin
|
| December 2022 |
adalimumab-aacf/Idacio |
adalimumab/Humira
|
| May 2023 |
adalimumab-aaty/Yuflyma |
adalimumab/Humira
|
| August 2023 |
natalizumab-sztn/Tyruko |
natalizumab/Tysabri
|
| September 2023 |
tocilizumab-bavi/Tofidence |
tocilizumab/Actemra
|
| October 2023 |
ustekinumab-auub/Wezlana |
ustekinumab/Stelara
|
| December 2023 |
bevacizumab-tnjn/Avzivi |
bevacizumab/Avastin
|
| February 2024 |
adalimumab-ryvk/Simlandi |
adalimumab/Humira
|
| March 2024 |
denosumab-bbdz/Jubbonti |
denosumab/Prolia
|
| March 2024 |
denosumab-bbdz/Wyost |
denosumab/Xgeva
|